Analyst Ratings

Upgrades, downgrades, and outlook changes from major analysts.

Coverage of analyst actions including upgrades, downgrades, initiations, and price-target changes. This category tracks how institutional research influences market perception, momentum shifts, and short-term price behavior.

Articles

3,516 total articles

Barclays Increases Tesla’s Price Target Following Introduction of Driverless Robotaxi Service in Austin

Barclays Increases Tesla’s Price Target Following Introduction of Driverless Robotaxi Service in Austin

Barclays has revised Tesla's stock price target upward to $360 while retaining an Equalweight rating, prompted by Tesla’s launch of fully autonomous robotaxi rides without safety monitors in Austin. Despite this technological milestone, the robotaxi fleet remains limited and below initial targets, with significant demand outstripping supply. Invest…

TD Cowen Elevates Fortinet to Buy Amid AI-Driven Opportunities

TD Cowen Elevates Fortinet to Buy Amid AI-Driven Opportunities

TD Cowen has raised its recommendation on Fortinet stock from Hold to Buy, augmenting its confidence in the company's robust financial performance and growth prospects enhanced by artificial intelligence adoption. The new price target of $100 signals significant upside potential from current levels, supported by Fortinet's healthy profit margins an…

Raymond James Increases Old National Bancorp’s Target Price to $28 Following Strong Q4 Performance

Raymond James Increases Old National Bancorp’s Target Price to $28 Following Strong Q4 Performance

Raymond James has adjusted its price target for Old National Bancorp stock to $28 from $25, maintaining a Strong Buy rating on the back of solid earnings results. The bank exceeded earnings expectations with $0.62 per share, supported by expanded net interest margins, improved loan growth, and disciplined expense management. Despite a slight revenu…

Raymond James Trims Abbott Laboratories Price Target Amid Concerns Over Nutrition Segment Performance

Raymond James Trims Abbott Laboratories Price Target Amid Concerns Over Nutrition Segment Performance

Raymond James has reduced its price target for Abbott Laboratories to $130 from $146 while maintaining an Outperform recommendation. The adjustment follows disappointing fourth-quarter results, particularly in the Nutrition segment, which have contributed to a recent share price decline nearing the 52-week low. Despite these challenges, the firm po…

BofA Cuts McCormick's Target Price Amid Margin Challenges; Highlights Consumer Segment Strength

BofA Cuts McCormick's Target Price Amid Margin Challenges; Highlights Consumer Segment Strength

Bank of America Securities reduced McCormick & Company’s price target from $89 to $80 after the spice and flavor company's fourth-quarter results revealed weaker-than-expected organic sales and a gross margin decline. The adjustment reflects several factors, including inventory impacts and increased costs. Meanwhile, McKesson Corporation’s strong q…